2019
DOI: 10.1093/annonc/mdz193
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background: The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) aimed to investigate whether a 3 months (3M) of oxaliplatin/fluoropyrimidine-based adjuvant chemotherapy (CT) is non-inferior to the 6-month (6M) administration in 3-year disease-free survival (3yDFS) in high-risk (HR) stage II or stage III colon cancer (CC). Methods: Hellenic Oncology Research Group (HORG)-IDEA randomized patients between 3M and 6M of CT with FOLFOX4 or CAPOX. Results: In total 1115 patients, 413 with HR stage I… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
16
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(16 citation statements)
references
References 12 publications
0
16
0
Order By: Relevance
“…The goal to investigate whether three months of adjuvant therapy with a fluoropyrimidine (FP)/ oxaliplatin combination compared to a treatment duration of 6 months would result in a markedly reduced toxicity without clinically meaningful loss of efficacy arose in several scientific groups. Therefore, an international project including six multicenter, randomized phase III trials conducted in 12 countries: Three or Six Colon Adjuvant (TOSCA) trial (Italy) [ 19 , 20 ], Short Course Oncology Treatment (SCOT) trial (UK) [ 21 ], IDEA France trial [ 22 ], intergroup Cancer and Leukemia Group B/Southwest Oncology Group (CALGB/SWOG) trial 80702 (US), Hellenic Oncology Research Group (HORG) trial (Greece) [ 23 ], and Adjuvant Chemotherapy for colon cancer with HIghEVidencE (ACHIEVE) trial (Japan) [ 24 , 25 ] was initiated, aiming a preplanned combined analysis.…”
Section: Idea Collaboration: Limiting Cumulative Doses Of Oxaliplamentioning
confidence: 99%
See 1 more Smart Citation
“…The goal to investigate whether three months of adjuvant therapy with a fluoropyrimidine (FP)/ oxaliplatin combination compared to a treatment duration of 6 months would result in a markedly reduced toxicity without clinically meaningful loss of efficacy arose in several scientific groups. Therefore, an international project including six multicenter, randomized phase III trials conducted in 12 countries: Three or Six Colon Adjuvant (TOSCA) trial (Italy) [ 19 , 20 ], Short Course Oncology Treatment (SCOT) trial (UK) [ 21 ], IDEA France trial [ 22 ], intergroup Cancer and Leukemia Group B/Southwest Oncology Group (CALGB/SWOG) trial 80702 (US), Hellenic Oncology Research Group (HORG) trial (Greece) [ 23 ], and Adjuvant Chemotherapy for colon cancer with HIghEVidencE (ACHIEVE) trial (Japan) [ 24 , 25 ] was initiated, aiming a preplanned combined analysis.…”
Section: Idea Collaboration: Limiting Cumulative Doses Of Oxaliplamentioning
confidence: 99%
“…In this risk group, results are heterogenous: The trial with the largest portion, SCOT, has shown no relevant differences between 3 and 6 months regarding 3-yr DFS (HR 0.988, 95% CI, 0.746 to 1.31). Other trials also failed to show non-inferiority (HORG: HR 1.05, 95% CI, 0.68 to 1.63) [ 23 ], ACHIEVE-2 (HR 1.12, 95% CI 0.67 to 1.87) [ 33 ]. However, the Italian TOSCA trial has shown a superiority in relapse-free survival for the 6 months treatment duration (HR 1.41; 95% CI 1.05 to 1.89) [ 34 ] although the 5-yr DFS was similar [ 20 ].…”
Section: Idea Collaboration: Limiting Cumulative Doses Of Oxaliplamentioning
confidence: 99%
“…Nowadays, after the IDEA collaboration for high-risk stage II colon cancer, the choice of appropriate treatment may become even more complicated. 17,18 A more detailed stratification of stage II and III colon cancer patients according to the risk of recurrence will allow physicians and patients to make more informed decisions towards tailoring the adjuvant regimen to refine the expectations of balancing the benefit and toxicity of chemotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…The GMS now requires validation and could provide a platform on which to develop personalized treatment approaches for CRC, which is also important for adjuvant chemotherapy, where biomarkers are lacking. For example, the SCOT trial recently demonstrated patients receiving CAPOX (capecitabine and oxaliplatin) have similar survival with 3-versus 6-months duration, whereas patients receiving FOLFOX (bolus and infused fluorouracil with oxaliplatin) may benefit from 6-months duration 18,19 . Therefore, it is important to identify patients who may benefit from a longer and more intensive chemotherapy regimen.…”
Section: Introductionmentioning
confidence: 99%